ContraVir Pharmaceuticals to Present Three Posters at the 53rd Annual International Liver Congress™
April 03 2018 - 6:00AM
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical
company focused on the development and commercialization of
therapeutic drugs for the treatment of hepatitis B virus (HBV),
announced today that three abstracts have been accepted for poster
presentations by the Scientific Program Committee of The
International Liver Congress™ 2018 to be held in Paris, France from
April 11-15, 2018.
Robert Foster, Pharm D., Ph.D, Chief Scientific Officer of
ContraVir Pharmaceuticals, will present all three posters and will
be available for interviews onsite at the ILC Press Office.
Abstract #1: Pharmacokinetic-Pharmacodynamic
Modeling of Tenofovir Exalidex in HBV Subjects
- Abstract Number: 3094
- Date and Time: April 13, 2018 from 9:00
AM to 5:00 PM
- Session: Viral Hepatitis B/D:
Therapy
Abstract #2: Assessing the in
vitro anti-HBV Activity of Combinations including CRV431,
TXL, and Prototype Capsid Assembly Modulators
- Abstract Number: 2615
- Date and Time: April 14, 2018 from 9:00
AM to 5:00 PM
- Session: Viral Hepatitis A, B, C, D, E:
Virology
Abstract #3: HBV Peptide Array Demonstrates
Candidate Mechanisms of CRV431 Anti-HBV Activity
- Abstract Number: 2624
- Date and Time: April 14, 2018 from 9:00
AM to 5:00 PM
- Session: Viral Hepatitis A, B, C, D, E:
Virology
About ContraVir Pharmaceuticals ContraVir is a
biopharmaceutical company focused on the development and
commercialization of targeted antiviral therapies with a specific
focus on developing a potentially curative therapy for hepatitis B
virus (HBV). The company is developing two novel anti-HBV compounds
with complementary mechanisms of action. TXL™, designed to deliver
high intrahepatic concentrations of TFV while minimizing off-target
effects caused by high levels of circulating TFV (bone and kidney),
recently completed a Phase 2a trial. CRV431, the other anti-HBV
compound, is a next-generation cyclophilin inhibitor with a unique
structure that increases its potency and selective index against
HBV. In vitro and in vivo studies have thus far demonstrated that
CRV431 reduces HBV DNA and other viral proteins, including surface
antigen (HBsAg). For more information
visit www.contravir.com
For further information, please contact: Sharen
Pyatetskaya Director of Investor Relations sp@contravir.com; (732)
902-4028
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Sep 2023 to Sep 2024